IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

May 24, 2024

Primary Completion Date

May 24, 2026

Study Completion Date

November 24, 2026

Conditions
Heart Failure, SystolicIron Deficiencies
Interventions
DRUG

Iron Carboxymaltose

Iron Carboxymaltose 500 mg. 2 vials administered IV.

DRUG

Dapagliflozin 10mg Tab

Dapagliflozin 10mg Tab, PO, onde a day.

DRUG

Placebo of Iron Carboxymaltose

Solution Sodium Chloride 0,9% 100 ml, IV, once.

DRUG

Placebo of Dapagliflozin

Equal shape and appearance tab as the tab containing Dapagliflozin 10 mg

Trial Locations (1)

90450120

Hospital de Clínicas de Porto Alegre, Porto Alegre

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Vifor Pharma

INDUSTRY

lead

Hospital de Clinicas de Porto Alegre

OTHER